IP Library Granted Patent US 12691114
Granted Patent B2
US 12691114 · App. 17/794,820 · Granted Jul 28, 2026

Compositions for inhibition of herpesviruses

Inventor: Ravit Boger (Baltimore, MD)
Assignee: The Medical College of Wisconsin, Inc.
A61K31/4985A61K31/341A61K31/407A61K31/454A61K31/475A61K31/496A61K31/517A61K31/522A61P31/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12691114
App. No.
17/794,820
Granted
Jul 28, 2026
Kind
B2
Abstract

The disclosure herein provides compounds of formulas I-V which are useful in the inhibition of viral diseases in a subject. In some embodiments, the compounds of formulas I-V are useful in the inhibition of herpes viruses.

Claims (8)

1 . A method of inhibiting a human herpesvirus in a subject in need thereof, comprising administering to the subject a compound of formula I or a pharmaceutical composition thereof comprising a pharmaceutically acceptable carrier, wherein formula I is:

or a salt, solvate, or stereoisomer thereof,

wherein R 1 is a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl optionally substituted with one or more amidinyl, guanidinyl, phosphate, sulfate, tetrazole, 3-hydroxyisoxazole, secondary amides, sulfonamides, sulfonyl ureas, acylamidines, acylguanidines, having 1 to 10 carbon atoms and linked via a C 1 -C 3 alky group.

2 . The method of claim 1 , wherein the compound is formula I and selected from the group consisting of:

3 . The method of claim 1 , wherein the herpesvirus is selected from the group consisting of human herpesvirus 1 (HHV-1), human herpesvirus 2 (HHV-2), human herpesvirus 3 (HHV-3), human herpesvirus 4 (HHV-4), human herpesvirus 5 (HHV-5), human herpesvirus 61 (HHV-6), human herpesvirus 7 (HHV-7), and human herpesvirus 8 (HHV-8).

4 . The method of claim 3 , wherein the herpesvirus is HHV-5, and further wherein the HHV-5 is ganciclovir resistant.

5 . The method of claim 1 , further comprising administering more than one biologically active agent.

6 . The method of claim 1 , further comprising administering ganciclovir or letermovir.